about
The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer.Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinomaChallenges in molecular testing in non-small-cell lung cancer patients with advanced disease.Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials.An immunogenomic stratification of colorectal cancer: Implications for development of targeted immunotherapy.Time to adjuvant chemotherapy following colorectal cancer resection is associated with an improved survival.Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors.Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR).BRAF-mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal CancerThe role of B lymphocytes in the immuno-biology of non-small-cell lung cancerBevacizumab (Avastin)
P50
Q36316643-D4926D6C-F7B5-4FCF-AFE4-3D6BA830FA86Q36661995-4E23099E-D456-49CB-B234-598119088960Q38947180-18EDD82A-40BC-4119-A2B7-5FE17E0ED98AQ39086354-9B44F968-E17B-419D-9362-9541BB2ACE74Q39833507-8C1746C0-4573-40F3-BD78-80983B823736Q42639244-9CF1A3CE-32C2-4414-A7AD-72A83A8F3AAAQ48117450-3A94DC59-7091-4AEA-9BEF-54F5582E21E3Q50066241-19702376-3A0E-43B0-B4D4-3E2CEFF343A0Q50767775-48660C1B-9126-48C3-8058-ECA5A38970A9Q53476716-E8622763-1C01-4E10-9311-EB58E72E992EQ89663329-01C0922E-2407-45D7-B487-29476EA5082EQ92417123-FC6D7BF6-BD46-4E72-B154-ECF9F5B1D75CQ95809251-E94CA068-073F-49DE-B11E-7E3EF6995D40
P50
description
researcher
@en
wetenschapper
@nl
name
Gary Middleton
@en
Gary Middleton
@nl
type
label
Gary Middleton
@en
Gary Middleton
@nl
prefLabel
Gary Middleton
@en
Gary Middleton
@nl
P31
P496
0000-0001-5695-3474